A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.
Fei XuQiufan ZhengWen XiaQuchang OuyangDanmei PangZhongyu YuanYanxia ShiRoujun PengQianyi LuShu-Sen WangPublished in: The oncologist (2020)
Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in patients with ER-positive/HER2-negative advanced breast cancer who have no disease progression after first-line chemotherapy.
Keyphrases
- epidermal growth factor receptor
- phase ii study
- locally advanced
- tyrosine kinase
- advanced non small cell lung cancer
- rectal cancer
- endothelial cells
- squamous cell carcinoma
- radiation therapy
- induced pluripotent stem cells
- clinical trial
- type diabetes
- stem cells
- randomized controlled trial
- estrogen receptor
- polycystic ovary syndrome
- breast cancer risk
- pluripotent stem cells
- adipose tissue
- study protocol
- childhood cancer